INSIGHT FLU005: An Anti-Influenza Virus Hyperimmune Intravenous Immunoglobulin Pilot Study

Autor: Mamta K. Jain, Tauseef Rehman, P. Coburn, Alain G. DuChene, K. Quan, Paul F. Riska, Jennifer A. Whitaker, Adriana Sanchez, L. H. Makohon, Fred M. Gordin, Norman Markowitz, Julia A. Metcalf, Edward M. Gardner, C. Solorzano, John H. Beigel, Elizabeth Finley, A. Shoen, D. Bigley, J. Moghe, T. Petersen, Marie L. Hoover, Jocelyn Voell, H. Clifford Lane, Venn Natarajan, B. Omotosho, Nicole Engen, J. Scott, John Tierney, Robin Dewar, Timothy M. Uyeki, Barbara Standridge, James D. Neaton, Stacey A. Rizza, Eileen Denning, Richard T. Davey, L. Harlow, Abdel Babiker, Deborah Wentworth, H Preston Holley, Gordon E. Thompson, John D. Baxter, L. L. Faber, Raquel Nahra, M. Harrison, R. Mcconnell, Zelalem Temesgen, Hari Polenakovik
Rok vydání: 2015
Předmět:
0301 basic medicine
Adult
Male
Adolescent
Orthomyxoviridae
Pilot Projects
medicine.disease_cause
Antibodies
Viral
Virus
Placebos
03 medical and health sciences
Young Adult
Major Articles and Brief Reports
0302 clinical medicine
Influenza A Virus
H1N1 Subtype
Double-Blind Method
Pandemic
Influenza
Human
Influenza A virus
medicine
Immunology and Allergy
Humans
030212 general & internal medicine
Aged
Aged
80 and over
biology
business.industry
Influenzavirus B
Influenza A Virus
H3N2 Subtype
Antibody titer
Immunization
Passive
virus diseases
Immunoglobulins
Intravenous
Hemagglutination Inhibition Tests
Middle Aged
biology.organism_classification
Virology
Influenza B virus
030104 developmental biology
Infectious Diseases
Treatment Outcome
Immunization
Immunology
biology.protein
Female
Antibody
business
Zdroj: The Journal of infectious diseases. 213(4)
ISSN: 1537-6613
Popis: Hemagglutination inhibition (HAI) antibody responses to anti–influenza virus hyperimmune intravenous immunoglobulin (hIVIG) were characterized. Thirty-one patients with influenza during the 2013–2014 season were randomly assigned to receive 0.25 g/kg of hIVIG (n = 16) or placebo (n = 15). For hIVIG recipients, the ratio of geometric mean titers (1 hour after infusion/before infusion) was 4.00 (95% confidence interval [CI], 2.61–6.13) for 2009 pandemic influenza A(H1N1) and 1.76 (95% CI, 1.33–2.32) for influenza A(H3N2) and influenza B. Among patients with 2009 pandemic influenza A(H1N1), ratios for hIVIG (n = 9) versus placebo (n = 8) were higher 1 hour after infusion (3.9 [95% CI, 2.3–6.7]) and sustained through day 3 (2.0 [95% CI, 1.0–4.0]). hIVIG administration significantly increases HAI titer levels among patients with influenza, supporting the need to perform a clinical outcomes study. Clinical trials registration: NCT02008578.
Databáze: OpenAIRE
Externí odkaz: